Literature DB >> 15161446

Comprehensive approach to advanced primary and recurrent ovarian cancer: a personal experience.

C Pablo Carmignani1, Paul H Sugarbaker.   

Abstract

Despite improvements in chemotherapy agents and schedules and new drug combinations, epithelial ovarian cancer remains a leading cause of gynecologic cancer death in Western countries. It is usually diagnosed at late stages of the disease, which makes complete surgical resection technically more difficult. The targeted comprehensive approach described in this review includes cytoreductive surgery and perioperative intraperitoneal chemotherapy. The goal of this aggressive therapy is to remove all the macroscopic disease with the use of peritonectomy procedures and visceral resections, and also to eradicate microscopic disease using heated intraoperative intraperitoneal chemotherapy and early postoperative intraperitoneal chemotherapy. Patients that received a complete cytoreduction followed by perioperative intraperitoneal chemotherapy had an improved survival, with reasonable morbidity and mortality, as compared with those who received incomplete cytoreduction.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15161446     DOI: 10.1586/14737140.4.3.477

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  2 in total

1.  The role of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer.

Authors:  Francisco C Muñoz-Casares; Sebastián Rufián; María J Rubio; Carlos J Díaz; Rafael Díaz; Angela Casado; Alvaro Arjona; María C Muñoz-Villanueva; Jordi Muntané
Journal:  Clin Transl Oncol       Date:  2009-11       Impact factor: 3.405

2.  Intra-operative intra-peritoneal chemotherapy with cisplatin in patients with peritoneal carcinomatosis of ovarian cancer.

Authors:  Emmanuel Guardiola; Delphine Delroeux; Bruno Heyd; Marielle Combe; Veronique Lorgis; Martin Demarchi; Ulrich Stein; Bernard Royer; Bruno Chauffert; Xavier Pivot
Journal:  World J Surg Oncol       Date:  2009-02-09       Impact factor: 2.754

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.